LINC01222: A Long Intergenic Non-Protein Coding RNA (G102800316)

Target Name: LINC01222

NCBI ID: G102800316

LINC01222

Other Name(s): long intergenic non-protein coding RNA 1222 | Long intergenic non-protein coding RNA 1222 | TCONS_00000112

LINC01222: A Long Intergenic Non-Protein Coding RNA

Non-Protein Coding RNAs (NP-CRNAs) have emerged as a promising source of drug targets and biomarkers due to their diverse functions and the potential to regulate gene expression. One class of NP-CRNAs, called long intergenic non-protein coding RNAs (long INs), have been identified and are characterized by their ability to span multiple exons within a gene. In this article, we will focus on LINC01222, a long IN that has been identified and characterized as a potential drug target and biomarker.

LINC01222 is a 21-kcal RNA molecule that was identified using RNA sequencing (RNA-seq) data from the human transcriptome. It is characterized by its ability to span multiple exons, with the first exon encoded as UTR1 and the last exon encoded as a putative protein-coding gene. LINC01222 is part of a growing family of long INs, including INs01221 and INs01223, which have been characterized for their ability to regulate gene expression and function.

Functional characterization of LINC01222 has shown that it plays a role in cell signaling and development. LINC01222 was shown to be highly expressed in various tissues and cell types, including brain, heart, and cancer. Additionally, LINC01222 was shown to play a role in regulating gene expression in various cell types, including cancer cells.

LINC01222 has also been shown to be a potential drug target. The high expression levels of LINC01222 in cancer cells make it an attractive target for cancer therapy. Additionally, the function of LINC01222 as a potential drug target was demonstrated by the ability to inhibit LINC01222 expression in cancer cells, leading to a decrease in cell proliferation.

In addition to its potential as a drug target, LINC01222 has also been shown to be a potential biomarker. The expression of LINC01222 has been shown to be associated with various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Additionally, the ability to regulate gene expression in LINC01222 has been used to identify potential biomarkers for these diseases, making LINC01222 a promising candidate for diagnostic applications.

In conclusion, LINC01222 is a long IN that has been identified and characterized as a potential drug target and biomarker. Its unique ability to span multiple exons and its function in cell signaling and development make it an attractive target for cancer and other diseases. Further research is needed to fully understand the role of LINC01222 in disease progression and to develop effective therapies based on LINC01222 as a potential biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1222

The "LINC01222 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01222 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets